INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees

Summary

Ebola virus disease (EVD) is a serious illness with a high fatality rate. Currently only one vaccine is available, VSV-ZEBOV/Ervebo; this vaccine is clinically effective and has been deployed as a preventive measure during recent Ebola outbreaks. The durability of protection afforded by this vaccine is unknown, however, and it is thought that a booster vaccination may be required to maintain immune responses. Recently, a synthetic DNA vaccine, INO-4201, was tested in humans and showed good immunogenicity and an enhanced safety profile. This study aims to test whether the DNA-based candidate INO-4201 can be used as a booster in healthy volunteers previously vaccinated with VSV-ZEBOV.

Timeline

Start

2021-09-01

Primary completion

2022-01-05

Completion

2022-05-11

Publications

• Huttner A, de La Vega MA, Boehm-Bosmani C, Boyer J, Eberhardt C, Fontannaz P, Gillespie E, Lemeille S, Morrow MP, Nepveu-Traversy ME, Orizu B, Reuschel EL, Roth R, Sharkhith H, Sylvester AJ, Vetter P, Humeau LM, Pignac-Kobinger J, Liebowitz D, Didierlaurent AM, Siegrist CA, Kobinger GP. A phase Ib, placebo-controlled randomized clinical trial of the Ebolavirus DNA vaccine candidate INO-4201 followed by electroporation as booster vaccination in healthy, rVSVDeltaG-ZEBOV-GP-primed volunteers (Boost-EBOV). Clin Microbiol Infect. 2026 Jul;32(7):1158-1164. doi: 10.1016/j.cmi.2026.01.019. Epub 2026 Jan 27.

Drugs

Indications